Standard
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. / Papp, Kim A; Strober, Bruce; Augustin, Matthias; Calabro, Steve; Londhe, Anil; Chevrier, Marc; Investigators, PSOLAR; Committee, Steering.
In:
J DRUGS DERMATOL, Vol. 11, No. 10, 10, 2012, p. 1210-1217.
Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Papp, KA, Strober, B
, Augustin, M, Calabro, S, Londhe, A, Chevrier, M, Investigators, PSOLAR & Committee, S 2012, '
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.',
J DRUGS DERMATOL, vol. 11, no. 10, 10, pp. 1210-1217. <
http://www.ncbi.nlm.nih.gov/pubmed/23134986?dopt=Citation>
APA
Papp, K. A., Strober, B.
, Augustin, M., Calabro, S., Londhe, A., Chevrier, M., Investigators, PSOLAR., & Committee, S. (2012).
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J DRUGS DERMATOL,
11(10), 1210-1217. [10].
http://www.ncbi.nlm.nih.gov/pubmed/23134986?dopt=Citation
Vancouver
Papp KA, Strober B
, Augustin M, Calabro S, Londhe A, Chevrier M et al.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J DRUGS DERMATOL. 2012;11(10):1210-1217. 10.
Bibtex
@article{6b2068abefea40768a253d785044b206,
title = "PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.",
abstract = "Long-term observational studies can better characterize the impact of systemic agents on psoriasis.",
keywords = "Adult, Humans, Male, Female, Middle Aged, Prospective Studies, Body Mass Index, Data Interpretation, Statistical, Body Surface Area, *Registries, Obesity/complications, Antibodies, Monoclonal/*adverse effects/therapeutic use, Arthritis, Psoriatic/complications, Cardiovascular Diseases/complications, Immunologic Factors/*adverse effects/therapeutic use, Phototherapy, *Product Surveillance, Postmarketing, Psoriasis/complications/pathology/*therapy, Adult, Humans, Male, Female, Middle Aged, Prospective Studies, Body Mass Index, Data Interpretation, Statistical, Body Surface Area, *Registries, Obesity/complications, Antibodies, Monoclonal/*adverse effects/therapeutic use, Arthritis, Psoriatic/complications, Cardiovascular Diseases/complications, Immunologic Factors/*adverse effects/therapeutic use, Phototherapy, *Product Surveillance, Postmarketing, Psoriasis/complications/pathology/*therapy",
author = "Papp, {Kim A} and Bruce Strober and Matthias Augustin and Steve Calabro and Anil Londhe and Marc Chevrier and PSOLAR Investigators and Steering Committee",
year = "2012",
language = "English",
volume = "11",
pages = "1210--1217",
journal = "J DRUGS DERMATOL",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "10",
}
RIS
TY - JOUR
T1 - PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
AU - Papp, Kim A
AU - Strober, Bruce
AU - Augustin, Matthias
AU - Calabro, Steve
AU - Londhe, Anil
AU - Chevrier, Marc
AU - Investigators, PSOLAR
AU - Committee, Steering
PY - 2012
Y1 - 2012
N2 - Long-term observational studies can better characterize the impact of systemic agents on psoriasis.
AB - Long-term observational studies can better characterize the impact of systemic agents on psoriasis.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Prospective Studies
KW - Body Mass Index
KW - Data Interpretation, Statistical
KW - Body Surface Area
KW - Registries
KW - Obesity/complications
KW - Antibodies, Monoclonal/adverse effects/therapeutic use
KW - Arthritis, Psoriatic/complications
KW - Cardiovascular Diseases/complications
KW - Immunologic Factors/adverse effects/therapeutic use
KW - Phototherapy
KW - Product Surveillance, Postmarketing
KW - Psoriasis/complications/pathology/therapy
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Prospective Studies
KW - Body Mass Index
KW - Data Interpretation, Statistical
KW - Body Surface Area
KW - Registries
KW - Obesity/complications
KW - Antibodies, Monoclonal/adverse effects/therapeutic use
KW - Arthritis, Psoriatic/complications
KW - Cardiovascular Diseases/complications
KW - Immunologic Factors/adverse effects/therapeutic use
KW - Phototherapy
KW - Product Surveillance, Postmarketing
KW - Psoriasis/complications/pathology/therapy
M3 - SCORING: Journal article
VL - 11
SP - 1210
EP - 1217
JO - J DRUGS DERMATOL
JF - J DRUGS DERMATOL
SN - 1545-9616
IS - 10
M1 - 10
ER -